Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA from Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA

Int J Mol Sci. 2024 Apr 11;25(8):4252. doi: 10.3390/ijms25084252.

Abstract

Circulating tumor DNA (ctDNA) is a promising biomarker, reflecting the presence of tumor cells. Sequencing-based detection of ctDNA at low tumor fractions is challenging due to the crude error rate of sequencing. To mitigate this challenge, we developed ultra-deep mutation-integrated sequencing (UMIseq), a fixed-panel deep targeted sequencing approach, which is universally applicable to all colorectal cancer (CRC) patients. UMIseq features UMI-mediated error correction, the exclusion of mutations related to clonal hematopoiesis, a panel of normal samples for error modeling, and signal integration from single-nucleotide variations, insertions, deletions, and phased mutations. UMIseq was trained and independently validated on pre-operative (pre-OP) plasma from CRC patients (n = 364) and healthy individuals (n = 61). UMIseq displayed an area under the curve surpassing 0.95 for allele frequencies (AFs) down to 0.05%. In the training cohort, the pre-OP detection rate reached 80% at 95% specificity, while it was 70% in the validation cohort. UMIseq enabled the detection of AFs down to 0.004%. To assess the potential for detection of residual disease, 26 post-operative plasma samples from stage III CRC patients were analyzed. From this we found that the detection of ctDNA was associated with recurrence. In conclusion, UMIseq demonstrated robust performance with high sensitivity and specificity, enabling the detection of ctDNA at low allele frequencies.

Keywords: DNA mutation; UMI-mediated error suppression; cell-free tumor DNA; cfDNA; clonal hematopoiesis; colorectal cancer; ctDNA; liquid biopsy; minimal residual disease; next-generation sequencing.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor* / blood
  • Biomarkers, Tumor* / genetics
  • Cell-Free Nucleic Acids / blood
  • Cell-Free Nucleic Acids / genetics
  • Circulating Tumor DNA* / blood
  • Circulating Tumor DNA* / genetics
  • Colorectal Neoplasms* / blood
  • Colorectal Neoplasms* / diagnosis
  • Colorectal Neoplasms* / genetics
  • Female
  • Gene Frequency
  • High-Throughput Nucleotide Sequencing* / methods
  • Humans
  • Male
  • Middle Aged
  • Mutation*
  • Sensitivity and Specificity

Substances

  • Circulating Tumor DNA
  • Biomarkers, Tumor
  • Cell-Free Nucleic Acids